Standards of medical treatment and nutrition in Crohn's disease

Langenbeck's Archives of Surgery

Volumn 390, Issue 6, 2005, Pages 503-509

  Siegmund, Britta ^a   Zeitz, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

5 Aminosalicylates; Corticosteroids; Crohn's disease; Immunosuppressive agents; Nutrition; Therapy

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANALGESIC AGENT; AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PARACETAMOL; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL DISCOMFORT; ANUS FISTULA; ARTHRALGIA; BONE DENSITY; BONE FRAGILITY; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DIET THERAPY; DIGESTIVE SYSTEM INFLAMMATION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; PARENTERAL NUTRITION; PHENOTYPE; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NUTRITIONAL SUPPORT; QUALITY OF LIFE; STEROIDS;

EID: 27744592107     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-004-0498-3     Document Type: Review

References (43)

1. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182-205
2. Gasche C, Schölmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al (2000) A simple classification of Crohn's disease: report of Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8-15
3. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al (1990) Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98:811-818
4. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al (1994) Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 331:836-841
5. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al (1996) Oral budesonide for active Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 110:45-51
6. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, et al (1998) A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide/Mesalamine Study Group. N Engl J Med 339:370-374
7. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al (1994) A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331:842-845
8. Hoffmann J, Zeitz M (2003) Chronically active Crohn's disease. Z Gastroenterol 41:31-35
9. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al (1992) Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 102:1647-1653
10. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al (1984) European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86:249-266
11. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al (1993) Azathioprine combined with prednisone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 105:367-372
12. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
13. Camma C, Giunta M, Rosselli M, Cottone M, Sandborn W, Sutherland L, et al (1997) Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113:1465-1473
14. Cottone M, Camma C, Fellermann K, Steffen M, Stein J, Raedler A, et al (2000) Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 119:597
15. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C, et al (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2:CD000545
16. Pearson DC, May GR, Fick G, Sutherland LR, Ortiz Z, Shea B, et al (2000) Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 342:CD000067
17. Boulton-Jones JR, Pritchard K, Mahmoud AA, Hanauer SB, McDonald JW, Ortiz Z, et al (2000) The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 14:1561-1565
18. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al (1996) Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347:215-219
19. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342:1627-1632
20. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P (2000) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2:CD000951
21. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF (1999) Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44:625-628
22. Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, et al (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14:171-176
23. Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT (2000) Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 6:16-20
24. Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, et al (2001) Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 16:1-11
25. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1549
26. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR (2003) Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125:320-327
27. Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, et al (2001) A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 121:1064-1072
28. Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF, Sutherland LR (1985) Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study. Dtsch Med Wochenschr 110:1724-1730
29. Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123:132-142
30. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405
31. Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 23:29-34
32. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G, et al (2000) Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95:1949-1954
33. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G, et al (2002) Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46:328-346
34. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187-1193
35. Tromm A, May D, Almus E, Voigt E, Greving I, Schwegler U, et al (2001) Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 39:137-144
36. Parlak E, Kosar Y, Ulker A, Dagli U, Alkim C, Sahin B, et al (2001) Primary sclerosing cholangitis in patients with inflammatory bowel disease in Turkey. J Clin Gastroenterol 33:299-301
37. Zachos M, Tondeur M, Griffiths AM (2001) Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 3:CD000542
38. Heuschkel RB (2000) Enteral nutrition in children with Crohn's disease. J Pediatr Gastroenterol Nutr 31:575
39. Goh J, O'Morain CA (2003) Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 17:307-320
40. Clements D, Compston JE, Evans WD, Rhodes J (1993) Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 34:1543-1546
41. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P (2000) Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD000952
42. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al (2000) Biphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2:CD001347
43. von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G, et al (2000) Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 12:19-24